Who are Cardinacillin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Carboxybenzylpenicillin, Piperacillin And Tazobactam, Pipracil, Ticarcillin, TICARCILLIN, Pathocil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carindacillin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cardinacillin — Competitive Intelligence Brief

Cardinacillin (carindacillin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Penicillin-class Antibacterial. Area: Infectious Disease.

marketed Penicillin-class Antibacterial Infectious Disease Live · refreshed every 30 min

Target snapshot

Cardinacillin (carindacillin) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cardinacillin TARGET	carindacillin	Pfizer	marketed	Penicillin-class Antibacterial		1972-01-01
Carboxybenzylpenicillin	CARBENICILLIN		marketed	Penicillin-class Antibacterial	Muscarinic acetylcholine receptor M1	1982-01-01
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Pipracil	Piperacillin Sodium	Pfizer Inc.	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Beta-lactamase producing bacteria	1981-01-01
Ticarcillin	TICARCILLIN DISODIUM		marketed	Penicillin-class Antibacterial		1976-01-01
TICARCILLIN	TICARCILLIN		marketed	Penicillin-class Antibacterial		1976-01-01
Pathocil	DICLOXACILLIN	Pfizer	marketed	Penicillin-class Antibacterial	Muscarinic acetylcholine receptor M1	1968-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Penicillin-class Antibacterial class)

Pfizer · 5 drugs in this class
· 4 drugs in this class
Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cardinacillin — Competitive Intelligence Brief. https://druglandscape.com/ci/carindacillin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab